Split Fed Circuit refuses Teva 'skinny label' ruling review
14-02-2022
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
Teva urges Fed Circuit to save skinny label law from ‘nullification’
03-12-2020
Ralf Liebhold / Shutterstock.com
Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s (GSK) Coreg heart drug (Carvedilol).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva Pharmaceuticals, Coreg, GlaxoSmithKline, Coreg, Federal Circuit, Carve-out, Skinny Label
